lily glp 1 Lilly's diabetes drug ahead of Novo Nordisk's in Q2 market share < Pharma < Article Lilly's oral GLP-1 Foundayo (orforglipron)
Description
These factors should inform baseline discussions with your provider about starting dose and escalation pace
It has a high affinity to GLP-1R, strongly activating the GLP-1R Gs cAMP pathway without inducing measurable -arrestin recruitment signaling, which indicates it is a fully biased agonist
Additionally, patients often opt to discontinue this medication due to issues such as intolerance, loss of insurance coverage, affordability concerns, or pharmacy shortages
[DOI] [PMC free article] [PubMed] [Google Scholar] 156.Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al
Two top brands in the industry, Ro (Roman) and Hers, are competing for your business with different pricing models and medication kits
